Finance

Lists
Why is ANAB down 2.83%?
Dive Deeper
ANAB:NASDAQ
AnaptysBio Inc
$47.81
-2.83%
(-1.39) 1D
Oct 6, 2:27:17 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ANAB...
Open
$49.41
High
$49.41
Low
$47.35
Mkt. cap
1.41B
Avg. vol.
549.10K
Volume
270.63K
52-wk high
$72.36
52-wk low
$19.65
Beta
0.45
Shares outstanding
29.90M
No. of employees
104
Open
$49.41
High
$49.41
Low
$47.35
Mkt. cap
1.41B
Avg. vol.
549.10K
Volume
270.63K
52-wk high
$72.36
52-wk low
$19.65
Beta
0.45
Shares outstanding
29.90M
No. of employees
104
News stories
From web sources and news partners
About AnaptysBio Inc
CEO-
Employees104
Founded2005
HeadquartersSan Diego, California, United States
SectorBiotechnology
Websiteanaptysbio.com
Analyst ratings
Based on 7 analysts giving stock ratings to ANAB in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for ANAB in the last 3 months.
Highest
Current $47.81
$95.00 (+98.70%)
Average
$80.00 (+67.33%)
Lowest
$60.00 (+25.50%)
Analyst
Recommendation
Action
Price target
Projected
Date
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
$95.00
+98.7%
10/05/2026
Anupam Rama
J.P. Morgan
Buy
Reiterated
$60.00
+25.5%
09/30/2026
David Risinger
Leerink Partners
Buy
Maintained
$81.00
+69.4%
09/23/2026
Etzer Darout
Barclays
Buy
Maintained
$75.00
+56.9%
09/22/2026
Michael Yee
UBS
Buy
Reiterated
$76.00
+59%
09/22/2026
Joseph Thome
TD Cowen
Buy
Reiterated
-
-
08/25/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$93.00
+94.5%
07/21/2026
David Nierengarten
Wedbush
Buy
Reiterated
$75.00
+56.9%
03/31/2026
Emily Bodnar
H.C. Wainwright
Buy
Maintained
$66.00
+38%
03/30/2026
Joon Lee
Truist Financial
Hold
Maintained
$50.00
+4.6%
03/09/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
$85.00
+77.8%
03/05/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
$140.00
+192.8%
03/04/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Mar 2026
Jun 2026
Jun 2026
Sep 2026
Revenue
25.56M
27.49M
27.49M
-
Cost of goods sold
33.99M
-2.70M
-
-
Cost of revenue
33.99M
-2.70M
-
-
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
26.20M
15.52M
-
-
Operating expense
26.20M
15.52M
-
-
Total operating expenses
60.19M
12.81M
-
-
Operating income
-34.64M
14.67M
-
-
Other non operating income
-1.00K
-1.00K
-
-
EBT including unusual items
-52.84M
-4.17M
-
-
EBT excluding unusual items
-52.84M
-4.17M
-
-
Income tax expense
40.00K
-181.49M
-
-
Effective tax rate
-0.08%
4,348.13%
-
-
Other operating expenses
-
-
-
-
Net income
-52.88M
183.88M
-
-
Net profit margin
-206.93%
668.95%
-
-
Earnings per share
-1.84
-
4.93
-
Interest and investment income
2.65M
1.49M
-
-
Interest expense
-20.86M
-20.33M
-
-
Net interest expenses
-18.21M
-18.85M
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-34.51M
14.68M
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps